Medarex/Centocor Extend Long-Term Antibody Development Relationship
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J subsidiary has generated antibodies now in the clinic using Medarex’s UltiMAb technology, Medarex tells “The Pink Sheet” DAILY.
You may also be interested in...
Centocor: Ustekinumab Works in Psoriasis After One Year
Second Phase III pivotal study backs fewer-dose benefit
Centocor: Ustekinumab Works in Psoriasis After One Year
Second Phase III pivotal study backs fewer-dose benefit
Organon/Medarex Expand UltiMab Antibody Agreement To Focus On Novel Target
Firms will codevelop Medarex-identified target, interim CEO Lerner tells “The Pink Sheet” DAILY.